Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.20 -1.93% 112.00 544,213 16:20:05
Bid Price Offer Price High Price Low Price Open Price
111.40 112.00 114.00 111.20 113.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 163.21 18.16 1.37 81.8 604
Last Trade Time Trade Type Trade Size Trade Price Currency
18:02:52 O 338 113.495 GBX

Alliance Pharma (APH) Latest News (1)

More Alliance Pharma News
Alliance Pharma Investors    Alliance Pharma Takeover Rumours

Alliance Pharma (APH) Discussions and Chat

Alliance Pharma Forums and Chat

Date Time Title Posts
19/5/202207:49Alliance Pharma pays Dividends1,731
21/8/201817:36A Canadian Stock Worth Watching1
07/11/201615:35Alliance Pharma plc1
15/7/201310:15ALLIANCE PHARMA – 2005 Strong Riser611

Add a New Thread

Alliance Pharma (APH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-07-01 16:03:57112.973,4033,844.37O
2022-07-01 15:53:26115.7250,00057,861.44O
2022-07-01 15:53:23115.7250,00057,861.44O
2022-07-01 15:39:48115.7250,00057,861.44O
2022-07-01 15:38:23112.0012,00013,440.00O
View all Alliance Pharma trades in real-time

Alliance Pharma (APH) Top Chat Posts

Alliance Pharma Daily Update: Alliance Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 114.20p.
Alliance Pharma Plc has a 4 week average price of 107p and a 12 week average price of 106p.
The 1 year high share price is 122p while the 1 year low share price is currently 95.50p.
There are currently 539,385,132 shares in issue and the average daily traded volume is 1,298,528 shares. The market capitalisation of Alliance Pharma Plc is £604,111,347.84.
wad collector: Strong looking share price graph, and some niche products. From a UK perspective the Nizoral brand is well placed bearing in mind the pressure for the NHS to not prescribe these borderline drug/consumer products. The Over The Counter alternatives are not well known and the brand name is strong. The other main products also have solid market positions , though I am a bit sceptical about Amberen menopausal vitamin pills . The only logical non-hrt medication is Vit D / Calcium and there are cheaper alternatives, though there will always be people willing to pay for an apparent specific treatment, like all these nonsense symptom -specific nurofen brands with no logical distinction. I guess it is also in the American market where you only have to look at the number of vaccine sceptics to realise that selling them vitamin pills is not about science.
wba1: 2vdm; reported buy and sell numbers are notoriously unreliable and price is more influenced by forward buy/sell orders than transactions already completed.
winnings1: APH could hardly be unaware of the price rigging taking place, but not sure whether there would be a duty to report
wba1: winnings1; no, that is not the question. Many similar arrangements occur across the industry for a variety of reasons. The question is whether APH made the arrangement with knowledge (either explicit or reasonably anticipated) of the activity of the distributor and benefitted from that activity. APH have been clear that they received no financial benefit from the pricing so only the former applies. This investigation falls under the cartel/anti-competitive behaviour function of the CMA and requires that APH be a participant in the behaviour. The only way I can see this being possible is if the CMA claim that APH entered the distribution agreement knowing of the pricing activity and were able to extract some benefit up front as a consequence (given that APH have made it clear they did not receive subsequent benefit). I can find no reference suggesting this is the claim of the CMA.
winnings1: The question one has to ask is why did APH part with a niche medicine whilst specializing in niche medicines themselve?
2vdm: wba. Agree with everything that you say, particularly about the FSA. This is a well managed company imo and I will continue to add on any dips. I'll look fwd to the appeal. APH have enough to pay for the current fine, but anyway feel that they are on solid ground to launch the appeal.
wba1: Interesting news today regarding the regulatory fine. It seems that the regulator is seeking to make examples of anyone and everyone even peripherally linked to the case in question. The last time I recall such overreach was the action of the FSA attempting to fine L&G millions for misselling, circa 2005. Their then CEO (Dave Prosser) took the regulator to court and eviscerated them, winning on every count. I would urge Alliance to do the same in this case. Regulators who ignore the facts for political purposes need to be thoroughly cleansed by judges who are not beholden to politicians. I will continue to hold APH as I have since buying in the low 40s. Their business model reminds me of an over the counter Galen - who made me good money many years ago. But I would urge them to exit the regulated prescription drugs sector. No need to have that complication for what is a small part of the business.
km18: From WealthOracleAM... The company we cover today is a very particular business, as it brings expertise to the marketing and regulatory management of products, ensuring it reaches a wide range of people. Alliance is a UK-based specialty pharmaceutical company. They are neither a manufacturer, nor a proper pharmaceuticals developer. This allows them to run an asset-light business (without all of the warehousing and logistics) and keep their focus on the areas of the business where they are experts. A simpler way to describe them would be a retailer for healthcare products. Acquisitions are a rare sight, with one done last year (Biogix) and the previous in 2012, resulting in a low goodwill figure. Fundamentals look healthy. Revenue CAGR is currently at 21.8%. The one-off drop in EPS from last year is mainly due to non-cash impairment and amortisation charges and the acquisition costs relating to Biogix transaction. This also pushed the ROCE down to 3.41%, but the ratio is rising by a CAGR of 7.99%. Free cash flow was strong supported by favourable movements in working capital and the total dividend was significantly ahead of 2019.
wad collector: This BB is humming with excitement ever since I acquired some in March. Usually shares drop when I buy them and the BB gets busy. I like this. Though won't buy much with the dividend. Interim results for the six months ended 30 June 2021 Strong growth from Consumer Healthcare brands and integration of Amberen complete Full year outlook in line with market expectations Alliance Pharma plc (AIM: APH), the international healthcare group, announces its interim results for the six months ended 30 June 2021 (the "Period"). HIGHLIGHTS -- The Group traded strongly in the Period with an excellent performance from Kelo-cote(TM), an uplift in revenue from Prescription Medicines and a significant contribution from recently acquired Amberen(TM) -- See-through revenue in total up 24% (+28% on a constant currency basis ("CCY")) to GBP80.9m; like-for-like ("LFL") see-through revenue, which excludes Amberen, up 9% (+12% CCY); statutory revenue up 27% to GBP78.6m (H1 2020 GBP61.7m) o Strong performance from Consumer Healthcare brands, with see-through revenue up 30% overall (+35% CCY) -- Kelo-cote revenue up 54% (+62% CCY) -- LFL Consumer Healthcare revenue up 8% (+12% CCY) o Prescription Medicines revenue up 12% (+12% CCY) -- Underlying gross margin up 4.7 % to 63.8% of see-through revenue (H1 2020: 59.1%), reflecting favourable changes in product mix; statutory gross margin up 3.1% to 65.6% (H1 2020: 62.5%) -- Underlying profit before tax up 24% to GBP20.1m (H1 2020: GBP16.3m); reported profit before tax GBP16.5m (H1 2020: GBP0.6m) -- Free cash flow GBP6.5m (H1 2020: GBP10.5m), reflecting the expected reversal of favourable working capital movements in Q4 2020 and the timing of sales within the Period -- Leverage reduced to 2.21 times from 2.43 times at December 2020 and expected to fall below 2.0 times by the end of the year -- Amberen integration complete and trading in line with management expectations -- Interim dividend payment of 0.563p, up 5% (interim dividend 2020: 0.536p)
winnings1: Has anyone here had a look at Beximco Pharmaceuticals (BXP) This company has been appointed to be the sole distributor of the Oxford vaccine for the whole of Bangladesh. The share price has risen significantly off late, but more to come IMHO. Cheers. But as always do your own research. ws
Alliance Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Alliance P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220702 02:32:30